Mark Gillyon-Powell
Biographic Data
| ID | 9638314 |
|---|---|
| NAME | Mark Gillyon-Powell |
| GIVEN NAMES | Mark |
| FAMILY NAME | Gillyon-Powell |
| SIGNATURE | GILLYON-POWELL M |
| AFFILIATIONS | NHS England |
| VERIFIED | No |
| TOTAL WORKS | 1 |
| TOTAL CITATIONS | 0 |
| WORKS AS AUTHOR | 1 |
| WORKS AS EDITOR | 0 |
| FIRST PUBLICATION YEAR | 2026 |
| LATEST PUBLICATION YEAR | 2026 |
| H-INDEX | 0 |
Can real-world scaling up HCV treatment in people who inject drugs be cost-saving
INTRODUCTION: UK is one of a few countries that are likely to meet WHO HCV elimination targets of reducing incidence to <2 per 100 person years in People Who Inject Drugs (PWID), but the economic case may be important for investment elsewhere and in future in UK. We illustrate the impact of real-world scaled-up HCV treatment to assess under what drug treatment costs could the investment be cost-saving. METHODS: We utilised a mathematical and econ…
No prominent works on this page.
Can real-world scaling up HCV treatment in people who inject drugs be cost-saving
INTRODUCTION: UK is one of a few countries that are likely to meet WHO HCV elimination targets of reducing incidence to <2 per 100 person years in People Who Inject Drugs (PWID), but the economic case may be important for investment elsewhere and in future in UK. We illustrate the impact of real-world scaled-up HCV treatment to assess under what drug treatment costs could the investment be cost-saving. METHODS: We utilised a mathematical and econ…
Economic model (1 work) · Hepatitis C virus research (1 work) · HIV, Drug Use, Sexual Risk (1 work) · HIV/AIDS Impact and Responses (1 work) · MEDLINE (1 work) · Scaling (1 work)